ArticleFrontiers in neurology2018
Therapeutic Inertia in the New Landscape of Multiple Sclerosis Care.
Article in Frontiers in neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Attitudes of Neurologists Toward Serum Neurofilament Light-Chain Testing in the Management of Relapsing-Remitting Multiple Sclerosis with Cognitive Impairment.Journal of personalized medicine · 2025Article
- Neurologists' Openness to Evidence-Based Innovation in Multiple Sclerosis Care: Individual and Structural Determinants.Neuropsychiatric disease and treatment · 2025Article
- A prospective survey on therapeutic inertia in psoriatic arthritis (OPTI'PsA).Rheumatology (Oxford, England) · 2024Article
- Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management.Therapeutic advances in neurological disorders · 2024Review
- Therapeutic inertia in the management of neuromyelitis optica spectrum disorder.Frontiers in neurology · 2024Article
- Unless Something Goes Wrong: Making Art to Understand and Mitigate the Risk of Therapeutic Inertia in the Treatment of Multiple Sclerosis.Journal of patient experience · 2023Article
- Intensifying approaches to address clinical inertia among cardiovascular disease risk factors: A narrative review.Patient education and counseling · 2022Review
- Therapeutic Decision-Making Under Uncertainty in the Management of Spinal Muscular Atrophy: Results From DECISIONS-SMA Study.Neurology and therapy · 2022Article
- Impact of telehealth on health care in a multiple sclerosis outpatient clinic during the COVID-19 pandemic.Multiple sclerosis and related disorders · 2022Article
- Review
- Therapeutic decisions under uncertainty for spinal muscular atrophy: The DECISIONS-SMA study protocol.PloS one · 2022Article
- High-Efficacy Disease-Modifying Therapies in People with Relapsing-Remitting Multiple Sclerosis: The Role of Risk Attitude in Treatment Decisions.The patient · 2021Article
- Behavioral aspects of nurse practitioners associated with optimal multiple sclerosis care in Spain.PloS one · 2021Article
- Psychometric Properties of the SymptoMScreen Questionnaire in a Mild Disability Population of Patients with Relapsing-Remitting Multiple Sclerosis: Quantifying the Patient's Perspective.Neurology and therapy · 2020Article
- Knowledge Is Power, but Is Ignorance Bliss? Optimising Conversations About Disease Progression in Multiple Sclerosis.Neurology and therapy · 2020Article
- Assessing Pharmacists' Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis.Pharmacy (Basel, Switzerland) · 2020Article
- Expert opinion on the use of cladribine tablets in clinical practice.Therapeutic advances in neurological disorders · 2020Review
- Practical Evidence-Based Recommendations for Patients with Multiple Sclerosis Who Want to Have Children.Neurology and therapy · 2018Review
- Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches.Neural regeneration research · 2018Review
- Usability of an Educational Intervention to Overcome Therapeutic Inertia in Multiple Sclerosis Care.Frontiers in neurology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The landscape of multiple sclerosis (MS) treatment is constantly changing. Significant heterogeneity exists in the efficacy and risks associated with these therapies. Therefore, clinicians have the challenge to tailor treatment based on several factors (disease activity level, risk of progression, individual patient preferences and characteristics, personal expertise, etc.), to identify the optimal balance between safety and efficacy. However, most clinicians have limited education in decision-making and formal training in risk management. Together, these factors may lead to therapeutic inertia (TI); defined as the absence of treatment initiation or intensification when therapeutic goals are unmet. TI may lead to suboptimal treatments choices, worse clinical outcomes, and more disability. This article provides a succinct overview on factors influencing TI in MS care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.